Stock Details
TAK is Takeda Pharmaceutical Company Limited's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 16.77$. Average daily volumn in 3 months 1.7M. Market cap 53.75B



Stock symbol : TAK. Exchange : NYSE. Currency : USD
Lastest price : 17.00$. Total volume : 1.35M. Market state PRE
Click reload if you want to check the lastest price on market!!!

Takeda Pharmaceutical Company Limited (TAK)
Last Price
17.00$
Change
-0.22
Volume
1.35M

Previous Close17.22
Open17.19
Day Range16.98-17.19
Bid16.89 x 2.9k
Ask17.28 x 4k
Volume1.35M
Average Volume1.7M
Market Cap53.75B
Beta1.13
52 Week Range15.30-19.97
Trailing P/E32.32
Foward P/E20.48
Dividend (Yield %)5.05%
Ex-Dividend Date2020-09-29



Financial Details


According to Takeda Pharmaceutical Company Limited's financial reports the company's revenue in 2021 were 3.2T an increase(0%) over the years 2020 revenue that were of 3.29T. In 2021 the company's total earnings were 376B while total earnings in 2020 were 44.24B( +754.55%).


Loading ...



Organization

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company, With American and British Roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US $19.299 billion in revenue during the 2018 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its in... dependent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and President of Takeda.

Takeda Pharmaceutical Company Limited_logo

Market Cap:
53.75B
Revenue:
3.2T
Total Assets:
12.91T
Total Cash:
966.22B


News about "Takeda Pharmaceutical Company Limited"

Here is why Takeda Pharmaceutical Company Limited (TAK) recent weekly performance of -0.82% shouldn’t bother you at All

For the readers interested in the stock health of Takeda Pharmaceutical Company Limited (TAK). It is currently valued at $17.00. When the transactions were called off in the previous session, Stock ...

Source from : investchronicle - 6 days ago


Takeda Pharmaceutical Company Limited (TAK) is primed for evolution with the beta value of 1.09

Takeda Pharmaceutical Company Limited (TAK) is priced at $16.98 after the most recent trading session. At the very opening of the session, the stock price was $17.03 and reached a high price of ...

Source from : investchronicle - 12 days ago


WFP and Takeda deepen partnership in West Africa to strengthen health emergency response_image

WFP and Takeda deepen partnership in West Africa to strengthen health emergency response

Download logo A new JPY 1.3 billion (approximately USD 10.8 million) contribution from Takeda Pharmaceutical Company Limited (Takeda) Global CSR Program to the World Food Programme (WFP) builds on ...

Source from : The Guardian Nigeria - 15 hours ago


Buy or Sell Takeda Pharmaceutical Company Limited (TAK) Stock Now | Don’t Try to Be a Top Gun

Takeda Pharmaceutical Company Limited (NYSE:TAK) went up by 1.49% from its latest closing price compared to the recent 1-year high of $19.97. The company’s stock price has collected -0.82% of loss in ...

Source from : newsheater - 7 days ago


Takeda breaks ground on first zero-emissions building in S'pore's pharmaceutical sector_image

Takeda breaks ground on first zero-emissions building in S'pore's pharmaceutical sector

The building represents a $19 million of the leading drugmaker's manufacturing site in Woodlands.. Read more at straitstimes.com.

Source from : The Straits Times - 1 days ago


A Lesson to Learn: Takeda Pharmaceutical Company Limited (TAK)

Takeda Pharmaceutical Company Limited (NYSE:TAK) went down by -0.93% from its latest closing price compared to the recent 1-year high of $19.97. The company’s stock price has collected 0.41% of gains ...

Source from : newsheater - 7 month ago


Takeda Agrees With Mirum Pharma For Approval, Commercialization Of Maralixibat In Japan

Mirum Pharmaceuticals, Inc. (MIRM) and Takeda Pharmaceutical Company Limited (TAK) have entered into an exclusive licensing agreement for the development and commercialization of maralixibat in Japan ...

Source from : Nasdaq - 2 days ago


BRIEF-Takeda Pharmaceutical Co Ltd Partners With Takeda To Develop Maralixibat For Rare Pediatric Liver Diseases In Japan

MIRUM PHARMACEUTICALS AND TAKEDA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE MARALIXIBAT FOR RARE PEDIATRIC LIVER DISEASES IN JAPAN * MIRUM PHARMACEUTICALS INC - TAKEDA WILL ...

Source from : Reuters on MSN.com - 2 days ago


Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases i

Partnership leverages Takeda’s leadership in rare disease, gastroenterology, and hepatology to advance maralixibat in a major marketFOSTER CITY, Calif. & OSAKA, Japan--(BUSINESS WIRE)--Mirum ...

Source from : 아크로팬 - 2 days ago


Takeda Pharma gets USFDA nod for cancer treatment EXKIVITY_image

Takeda Pharma gets USFDA nod for cancer treatment EXKIVITY

EXKIVITY, which was granted priority review and received Breakthrough Therapy Designation, Fast Track Designation and Orphan Drug Designation from the FDA, is the first and only approved oral therapy ...

Source from : Daily - 5 days ago


Global Immunoglobulins Market Outlook & Forecast Report 2021-2026 with CSL Limited, Takeda Pharmaceutical Company Limited, and Grifols S.A Dominating

The "Immunoglobulins Market - Global Outlook & Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. The global immunoglobulins market was valued at USD 13.59 billion in 2020 ...

Source from : 아크로팬 - 1 days ago


Takeda Pharmaceutical Co. Ltd.

1 Day 4502 -1.55% DJIA 0.30% S&P 500 0.20% Health Care/Life Sciences 0.13% Christophe Weber President, CEO & Representative Director Takeda Pharmaceutical Co., Ltd. Constantine Saroukos Chief ...

Source from : Wall Street Journal - 14 days ago


Takeda Pharmaceutical Company Limited 2022 Q1 - Results - Earnings Call Presentation

Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site ...

Source from : Seeking Alpha - 1 month ago


Japan’s MHLW to purchase 150 million doses of Novavax’ vaccine candidate manufactured by Takeda Pharma

Takeda Pharmaceutical Company Limited announced that the Government of Japan’s Ministry of Health, Labour and Welfare (MHLW) will purchase 150 million doses of Novavax’ vaccine candidate (TAK-019 in ...

Source from : Pharmabiz - 15 days ago


Takeda Pharmaceutical Company Limited (4502.T)

OSAKA, Japan & CAMBRIDGE, Mass., September 01, 2021--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the Phase 3 PANTHER (Pevonedistat-3001) study did not ...

Source from : Yahoo Finance - 22 days ago


Retinal Pharmaceuticals Market- A Comprehensive Study by Leading Players- Takeda, Bayer, Novartis_image

Retinal Pharmaceuticals Market- A Comprehensive Study by Leading Players- Takeda, Bayer, Novartis

The Worldwide Retinal Pharmaceuticals Market Report assesses developments relevant to the insurance industry and identifies key risks and vulnerabilities for the Worldwide Retinal Pharmaceuticals ...

Source from : openpr.com - 6 days ago


Research details developments in the Anti-Inhibitor Coagulant Complex Market future scenario by 2028 | Takeda Pharmaceutical

A worldwide analysis of devices focusing on market growth is carried out in the “Global Anti-Inhibitor Coagulant Complex Market Analysis to 2028.” The research is intended to offer an overview of the ...

Source from : manometcurrent.com - 14 days ago


Takeda Pharmaceutical Co. Ltd.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Source from : Barron's - 27 days ago


Takeda Pharmaceutical Co Ltd 4502

Narrow-moat Takeda reported first-quarter results with ... it is in line with our expectation of JPY 813 billion. The company reported core operating profit margin of 30.5%, which we think is ...

Source from : Morningstar%2c Inc. - 17 days ago


Takeda Pharmaceutical Co. Ltd. ADR

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Source from : Barron's - 14 days ago


Chancery Says Takeda Liable For AbbVie's Lupron Supply Lag

Japanese drugmaker Takeda Pharmaceutical Co. Ltd. is liable to distributor AbbVie Endocrine Inc. for breaching their supply agreement for cancer drug Lupron Depot, a Delaware Chancery judge ruled ...

Source from : Law360 - 15 hours ago


Takeda’s Exkivity Approved by U.S. FDA as First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC

The U.S. Food and Drug Administration approved Takeda Pharmaceutical Company Limited's Exkivity (mobocertinib) for the treatment of adult patients with locally advanced or metastatic non-small cell lu ...

Source from : PharmaLive - 7 days ago


FDA Approves Tissue-Based NGS Companion Diagnostic for Takeda's Targeted Therapy for NSCLC Patients with EGFR Exon20 Insertion Mutations_image

FDA Approves Tissue-Based NGS Companion Diagnostic for Takeda's Targeted Therapy for NSCLC Patients with EGFR Exon20 Insertion Mutations

who are candidates for EXKIVITY™ (mobocertinib), a targeted drug developed by Takeda Pharmaceutical Company Limited ("Takeda"). EXKIVITY is a small-molecule tyrosine kinase inhibitor (TKI ...

Source from : Yahoo Finance - 7 days ago


Zydus, Takeda Tell 3rd Circ. Antitrust Appeal In Right Place

Zydus Pharmaceuticals Inc. and Takeda Pharmaceutical Co. Ltd. have told the Third Circuit that Zydus' bid to revive antitrust counterclaims should not be moved to the Federal Circuit because patent ...

Source from : Law360 - 8 days ago


Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Phase 3 PANTHER (Pevonedistat-3001) study did not ...

Source from : PharmiWeb - 21 days ago


Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial

OSAKA, Japan & CAMBRIDGE, Mass., September 01, 2021--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the ...

Source from : Yahoo Finance - 21 days ago


Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial

Osaka, Japan & Cambridge, Mass., United States: Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Phase 3 PANTHER (Pevonedistat-3001) study did not ...

Source from : Business Wire - 20 days ago


FDA approves Takeda’s Exkivity for rare form of lung cancer

(NSCLC) market, becoming the first company to gain FDA approval for an oral drug targeted against a rare form of the disease. The FDA approved Exkivity (mobocertinib) to treat NSCLC with EGFR exon 20 ...

Source from : BioWorld - 6 days ago


Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Phase 3 PANTHER ...

Source from : Business Wire - 21 days ago


Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial

Takeda Pharmaceutical Company Limited ((TAK) ("Takeda") today announced that the Phase 3 PANTHER (Pevonedistat-3001) study did not achieve pre-defined statistical significance for the primary ...

Source from : Benzinga.com - 21 days ago


AbbVie's Ask for Takeda Production Injunction Found Not Enforceable_image

AbbVie's Ask for Takeda Production Injunction Found Not Enforceable

Since the injunction isn't being granted, Glasscock said there's no reason to expedite the rest of the case, which centers on a contractual dispute between the two drug companies.

Source from : Law - 12 days ago


Takeda to Manufacture and Provide 150 Million Doses of Novavax’ COVID-19 Vaccine Candidate to the Government of Japan

OSAKA, Japan, September 7, 2021 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Government of Japan’s Ministry of Health, Labour and Welfare (MHLW) will ...

Source from : PharmiWeb - 16 days ago


Takeda Receives Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVie

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the receipt of a decision by the Irish Tax Appeals Commission on July 30 ...

Source from : Business Wire - 1 month ago


Takeda (TAK) Hematology Candidate Fails in Late-Stage Study

Takeda Pharmaceutical Company Limited TAK announced that a phase III study evaluating its pipeline candidate, pevonedistat, in hematological disorders failed to reach its primary endpoint.

Source from : Nasdaq - 20 days ago


Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Phase 3 PANTHER (Pevonedistat-3001) study did not achieve pre-defined statistical significance for ...

Source from : wallstreet online - 21 days ago


Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial

OSAKA, Japan & CAMBRIDGE, Mass., September 01, 2021--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the Phase 3 PANTHER (Pevonedistat-3001) ...

Source from : Yahoo Finance - 21 days ago


BioLife Plasma Services Opens First All-Electric Plasma Donation Center

BioLife Plasma Services is part of Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), a global values-based, R&D-driven pharmaceutical company that produces and delivers plasma-based ...

Source from : Morningstar%2c Inc. - 1 month ago


Takeda must face Actos antitrust claims, 2nd Circuit says

(Reuters) - Takeda Pharmaceutical Co Ltd lost its bid at the 2nd U.S. Circuit ... an automatic 30-month stay of FDA approval. Several companies sought to make generic Actos in 2003 and 2004 ...

Source from : Reuters - 27 days ago


Novavax Shares Surge On Vaccine Supply Deal With Japan

What Happened: Japanese pharma giant Takeda Pharmaceutical Company Limited (NYSE: TAK) announced Monday that Japan's Health Ministry has agreed to purchase 150 million doses of Novavax's vaccine ...

Source from : MSN - 15 days ago


Pioneer Natural Resources Announces the Addition of Maria S. Jelescu Dreyfus to the Company's Board of Directors

Pioneer Natural Resources Company ("Pioneer" or the "Company") today announced the addition of Maria S. Jelescu Dreyfus to the Company's Board of Directors. Ms. Dreyfus is currently the Chief ...

Source from : Le Lézard - 1 days ago


Exelixis partner Takeda & Ono receive Japanese approval for Cabometyx in combo with Opdivo to treat unresectable or metastatic RCC

Exelixis, Inc. announced Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of Cabometyx (cabozantinib) in Japan, and Ono ...

Source from : Pharmabiz - 26 days ago


15 Best Pharmaceutical Stocks to Invest In

Takeda Pharmaceutical Company Limited (NYSE:TAK) is a Japanese pharmaceutical company. It is the largest pharmaceutical company in Asia by revenue. Its products include drugs and treatments for ...

Source from : Insider Monkey - 22 days ago


Takeda (TAK) Hematology Candidate Fails in Late-Stage Study

Takeda Pharmaceutical Company Limited TAK announced that a phase III study evaluating its pipeline candidate, pevonedistat, in hematological disorders failed to reach its primary endpoint. The study ...

Source from : Yahoo Finance - 17 days ago


BioLife Plasma Services Opens First All-Electric Plasma Donation Center

BioLife Plasma Services, part of the global biopharmaceutical company Takeda Pharmaceutical Company Limited, today announced the opening of an all-electric plasma donation center in Tukwila ...

Source from : wallstreet online - 1 month ago


Takeda adds second Genevant deal, boosting potential value of partnership beyond $900M

Building on a March deal leveraging lipid nanoparticle (LNP) technology from Genevant Sciences Corp. to fight liver fibrosis, Takeda Pharmaceutical Co. Ltd. has signed a second agreement with the ...

Source from : BioWorld - 29 days ago


Moderna to recall COVID-19 doses in Japan after stainless steel contaminants found

TOKYO, Sept 1 (Reuters) - Moderna Inc (MRNA.O) and Takeda Pharmaceutical Co Ltd (4502.T ... based on information from the companies' investigation, that it did not believe the particles of ...

Source from : Reuters - 21 days ago


Simetric Selected as a Venture Atlanta 2021 Presenting Company

Over $6.5 billion in funding awarded to date; leading tech investment conference continues to select large and diverse lineup of innovators from the Southeast's hottest tech markets. Simetric ...

Source from : Le Lézard - 1 days ago


Japan to get 150M doses of Novavax’s COVID-19 vaccine candidate

Osaka-based Takeda Pharmaceutical Company Limited said in a statement on Tuesday that Japan’s Ministry of Health, Labor and Welfare “will purchase 150 million doses of Novavax vaccine (TAK-019 ...

Source from : aa.com.tr - 16 days ago